The biotech stock plunged so much because the co-primary endpoint misses weren't even close. That's especially problematic because lirentelimab is Allokos' only pipeline candidate in clinical development.
Is the Allakos stock collapse a learning opportunity?
Dec 22, 2021 · The company announced disappointing results from two clinical studies. What happened Shares of Allakos ( ALLK 1.48% ) are crashing 88% lower as of 10:17 a.m ET on Wednesday. The huge decline came...
What are Allakos'stock price targets for the next 12 months?
Dec 22, 2021 · This is why it happened. The stock price of Allakos Inc (NASDAQ: ALLK) – a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases – fell by over 85% pre-market today. Investors are responding negatively to Allakos reporting data from ENIGMA 2, a 24-week Phase 3 randomized, double …
Does Allakos boast high insider ownership?
Apr 14, 2022 · Why Allakos Stock Sank 17.3% in February - Nasdaq nasdaq.com - March 7 at 12:17 PM Allakos cutting 35% of workforce, Lonza pact after clinical trial failures - San Francisco Business Times - The Business Journals
What are your Allakos (allK) stock predictions?
Apr 22, 2022 · Allakos' stock was trading at $58.30 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ALLK stock has decreased by 92.6% and is now trading at $4.30.
Why is Allakos stock dropping?
Why Allakos Stock Sank 17.3% in February In December, Allakos published devastating trial data for its lirentelimab monoclonal antibody treatment for eosinophilic gastrointestinal diseases (EGIDs), and the company's share price has continued to lose ground after its initial, precipitous pullback.
Is Allakos stock a good buy?
Is ALLAKOS Stock a good buy in 2022, according to Wall Street analysts? The consensus among 10 Wall Street analysts covering (NASDAQ: ALLK) stock is to Hold ALLK stock.
Why did ALLK stock drop today?
Shares of Allakos ( ALLK 2.63% ) are crashing 88% lower as of 10:17 a.m ET on Wednesday. The huge decline came after the company announced results from its phase 3 Enigma 2 and its phase 2/3 Kryptos clinical studies evaluating lirentelimab.Dec 22, 2021
Will Allakos stock go up?
Stock Price Forecast The 9 analysts offering 12-month price forecasts for Allakos Inc have a median target of 8.00, with a high estimate of 23.00 and a low estimate of 5.00. The median estimate represents a +85.19% increase from the last price of 4.32.
What is NAKD stock?
One explosive stock that has since fizzled this year is Naked Brand (NASDAQ:NAKD). Although shares nearly doubled in the year to date, recent months have seen NAKD stock cool down. This retailer of men's and women's swimwear and intimate clothing products has been hit hard by the pandemic.Dec 31, 2021
What happened to Allakos?
Why Allakos Stock Sank 17.3% in February In December, Allakos published devastating trial data for its lirentelimab monoclonal antibody treatment for eosinophilic gastrointestinal diseases (EGIDs), and the company's share price has continued to lose ground after its initial, precipitous pullback.
Is ALK a good stock to buy now?
The financial health and growth prospects of ALK, demonstrate its potential to outperform the market. It currently has a Growth Score of D. Recent price changes and earnings estimate revisions indicate this would not be a good stock for momentum investors with a Momentum Score of F.
Allakos Media Sentiment
Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.
Media Coverage
We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.
Allakos (NASDAQ ALLK) News Headlines Today
Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm.
Is Allakos a buy right now?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Allakos stock.#N#View analyst ratings for Allakos or view top-rated stocks.
What stocks does MarketBeat like better than Allakos?
Wall Street analysts have given Allakos a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Allakos wasn't one of them.
Are investors shorting Allakos?
Allakos saw a decline in short interest in the month of August. As of August 13th, there was short interest totaling 3,370,000 shares, a decline of 13.1% from the July 29th total of 3,880,000 shares. Based on an average daily trading volume, of 271,400 shares, the days-to-cover ratio is currently 12.4 days.
When is Allakos' next earnings date?
Allakos is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.#N#View our earnings forecast for Allakos.
How were Allakos' earnings last quarter?
Allakos Inc. (NASDAQ:ALLK) issued its earnings results on Sunday, August, 8th. The company reported ($1.07) EPS for the quarter, missing the Zacks' consensus estimate of ($1.06) by $0.01.#N#View Allakos' earnings history.
How has Allakos' stock been impacted by Coronavirus?
Allakos' stock was trading at $58.30 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ALLK shares have increased by 69.0% and is now trading at $98.50.#N#View which stocks have been most impacted by COVID-19.
What price target have analysts set for ALLK?
7 Wall Street analysts have issued 12 month price objectives for Allakos' shares. Their forecasts range from $76.53 to $230.00. On average, they anticipate Allakos' share price to reach $151.51 in the next twelve months.
Allakos Provides Business Update and Reports Second Quarter 2021 Financial Results
REDWOOD CITY, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today provided a business update and reported financial results for the second quarter ended June 30, 2021.
15 Stocks that Will Double In 2021
In this article, we discuss the 15 stocks that will double in 2021. If you want to skip our detailed analysis of these stocks, go directly to the 5 Stocks that Will Double In 2021. The economy of 2020 was closely linked to the COVID-19 pandemic. However, the vaccine rollout at the turn of the […]
3 Biotech Stocks That Could Double Soon
Wall Street analysts following these drugmakers think they can produce big gains in a short time frame.
Companies Like Allakos (NASDAQ:ALLK) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Moving Average Crossover Alert: Allakos (ALLK)
Allakos (ALLK) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Silicon Motion Technology, Allakos, Bloomin' Brands, Sally Beauty Holdings and Boyd Gaming highlighted as Zacks Bull and Bear of the Day
Silicon Motion Technology, Allakos, Bloomin' Brands, Sally Beauty Holdings and Boyd Gaming highlighted as Zacks Bull and Bear of the Day
Allakos Reports First Quarter 2021 Financial Results and Provides Business Update
REDWOOD CITY, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the first quarter ended March 31, 2021 and provided a business update.
